Table 1. Characteristics of articles included in the study (n=75).
| n (%) | |
|---|---|
| Year of publication | |
| 1991-1995 | 5 (6.7) |
| 1996-2000 | 23 (30.7) |
| 2001-2005 | 14 (18.7) |
| 2006-2011 | 33 (44.0) |
| Journal impact factor, quartiles (Q) | |
| Q1 | 44 (58.7) |
| Q2 | 13 (17.3) |
| Q3 | 5 (6.7) |
| Q4 | 1 (1.3) |
| None | 12 (16.0) |
| Journal subject category* | |
| Cardiac & cardiovasc. systems/peripheral vasc. disease | 22 (29.3) |
| Medicine, general & internal | 18 (24.0) |
| Pharmacology & pharmacy | 10 (13.3) |
| Health care sciences & services/health policy & serv. | 9 (12.0) |
| Endocrinology & metabolism | 3 (4.0) |
| Other/none | 13 (17.3) |
| Region of study | |
| Europe | 37 (49.3) |
| North America | 33 (44.0) |
| Other | 5 (6.7) |
| First author affiliation** | |
| Academia | 33 (44.0) |
| Private | 21 (28.0) |
| Hospital | 18 (24.0) |
| Other | 3 (4.0) |
| One or more author industry or consulting firm employee | |
| Yes | 31 (41.3) |
| No | 44 (58.7) |
| Funding source | |
| Industry | 48 (64.0) |
| Non-profit/Government | 14 (18.7) |
| No funding/none disclosed | 13 (17.3) |
| Interventions | |
| Statin versus statin | 23 (30.7) |
| Statin versus non-active alternative | 52 (69.3) |
| Prevention category | |
| Primary | 29 (38.7) |
| Secondary | 32 (42.7) |
| Both | 14 (18.7) |
*
Subject category as reported in the 2010 Journal Citation Report. Data do not equal 100% because of rounding errors.
**
The affiliation categories of the first author were mutually exclusive according to the following hierarchie: private > academia > hospital > other.